当前位置: 首页? 政策法规? 国外法规? (EU) No 382/2010:拒绝批准某些不涉及降低疾病风险和儿童成长、健康的食品健康声称(refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health)

(EU) No 382/2010:拒绝批准某些不涉及降低疾病风险和儿童成长、健康的食品健康声称(refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health)

扫描二维 分享好友和朋友圈
放大字体缩小字体2015-01-30 01:25:32 来源9a href="http://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1422259905542&uri=CELEX:32010R0382" target="_blank" rel="nofollow">EUROPE浏览次数9span id="hits">3401
核心提示?010??日,欧盟发布委员会条?EU) No 382/2010,拒绝批?种食品健康声称,分别如下?)天然美?reg;片和天然美胸?胶囊:NPU片剂可通过8-异戊烯基柚皮素的作用仿效女性丰胸;2)BimunoBT (BGOS)益生元有助于维持胃肠道健康;3)BimunoBT (BGOS)益生元有助于维持天然防御能力?)Gum PeriobalanceTM片剂及口香糖:Gum PeriobalanceTM结合正确的口腔卫生习惯,有助于重新平衡口腔微生物群并改善口腔健康、/div>
发布单位
EUROPEAN COMMISSION
EUROPEAN COMMISSION
发布文号 (EU) No 382/2010
发布日期 2010-05-06 生效日期 暂无
有效性状?/th> 废止日期 暂无
备注 2010??日,欧盟发布委员会条?EU) No 382/2010,拒绝批?种食品健康声称,分别如下?)天然美?reg;片和天然美胸?胶囊:NPU片剂可通过8-异戊烯基柚皮素的作用仿效女性丰胸;2)BimunoBT (BGOS)益生元有助于维持胃肠道健康;3)BimunoBT (BGOS)益生元有助于维持天然防御能力?)Gum PeriobalanceTM片剂及口香糖:Gum PeriobalanceTM结合正确的口腔卫生习惯,有助于重新平衡口腔微生物群并改善口腔健康、/td>

  COMMISSION REGULATION (EU) No 382/2010

  of 5 May 2010

  refusing to authorise certain health claims made on foods, other than those referring to the reduction of disease risk and to childrens development and health

  (Text with EEA relevance)

  THE EUROPEAN COMMISSION,

  Having regard to the Treaty on the Functioning of the European Union,

  Having regard to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods (1), and in particular Article 18(5) thereof,

  Whereas:

  (1) Pursuant to Regulation (EC) No 1924/2006 health claims made on food are prohibited unless they are authorised by the Commission in accordance with that Regulation and included in a list of permitted claims.

  (2) Regulation (EC) No 1924/2006 also provides that applications for authorisations of health claims may be submitted by food business operators to the national competent authority of a Member State. The national competent authority is to forward valid applications to the European Food Safety Authority (EFSA), hereinafter referred to as the Authority.

  (3) Following receipt of an application the Authority is to inform without delay the other Member States and the Commission and to deliver an opinion on a health claim concerned.

  (4) The Commission is to decide on the authorisation of health claims taking into account the opinion delivered by the Authority.

  (5) Following an application from The Natural Push-Up Company, submitted on 28 November 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Natural Push-Up? Tablets and Natural Push-Up? Capsules on female breast enhancement (Question No EFSA-Q-2008-784) (2). The claim proposed by the applicant was worded as follows: NPU Tablets imitate female breasts enhancement process by 8-PN (8-Prenylnaringenin).

  (6) On 5 June 2009, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Natural Push-Up? Tablets and Natural Push-Up? Capsules and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (7) Following an application from Clasado Ltd., submitted on 29 December 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of BimunoBT (BGOS) Prebiotic on maintaining a healthy gastro-intestinal function (Question No EFSA-Q-2009-00231) (3). The claim proposed by the applicant was worded as follows: Helps maintain a healthy gastro-intestinal (GI) function.

  (8) On 7 July 2009, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of BimunoBT (BGOS) Prebiotic and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (9) Following an application from Clasado Ltd., submitted on 15 July 2008 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of BimunoBT (BGOS) Prebiotic on support of the immune system (Question No EFSA-Q-2009-00230) (4). The claim proposed by the applicant was worded as follows: Supports your natural defences.

  (10) On 7 July 2009, the Commission and the Member States received the scientific opinion from the Authority which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of BimunoBT (BGOS) Prebiotic and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (11) Following an application from Sunstar Suisse S.A., submitted on 4 February 2009 pursuant to Article 13(5) of Regulation (EC) No 1924/2006, the Authority was required to deliver an opinion on a health claim related to the effects of Gum PeriobalanceTM tablets and chewing gum on oral health (Question No EFSA-Q-2009-00373) (5). The claim proposed by the applicant was worded as follows: Gum PeriobalanceTM, combined with a correct oral hygiene, helps re-balancing the oral microflora and improving oral health.

  (12) On 20 July 2009, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Gum PeriobalanceTM tablets and chewing gum and the claimed effect. Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.

  (13) The comments from the applicants and the members of the public received by the Commission, pursuant to Article 16(6) of Regulation (EC) No 1924/2006, have been considered when setting the measures provided for in this Regulation.

  (14) Health claims referred to in Article 13(1)(a) of Regulation (EC) No 1924/2006 are subject to the transition measures laid down in Article 28(5) of that Regulation only if they comply with the conditions therein mentioned, among which that they have to comply with the Regulation. As for the four claims subject to the present Regulation, the Authority concluded that a cause and effect relationship had not been established between the consumption of the foods and the claimed effects and thus they do not comply with the Regulation (EC) No 1924/2006, they could not benefit from the transition period foreseen in Article 28(5) of that Regulation. A transition period of six months is provided for to enable food business operators to adapt to the requirements laid down in this Regulation.

  (15) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health and neither the European Parliament nor the Council have opposed them,

  HAS ADOPTED THIS REGULATION:

  Article 1

  Health claims set out in the Annex to this Regulation shall not be included in the Community list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.

  However, they may continue to be used for six months after the entry into force of this Regulation.

  Article 2

  This Regulation shall enter into force on the 20th day following its publication in the Official Journal of the European Union.

  This Regulation shall be binding in its entirety and directly applicable in all Member States.

  Done at Brussels, 5 May 2010.

  For the Commission

  The President

  Jos Manuel BARROSO

ANNEX
Rejected health claims

Application Relevant provisions of Regulation (EC) No 1924/2006
Nutrient, substance, food or food category
Claim
EFSA opinion reference
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Natural Push-Up? Tablets and Natural Push-Up? Capsules
NPU Tablets imitate female breasts enhancement process by 8-PN (8-Prenylnaringenin)
Q-2008-784
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
BimunoBT (BGOS) Prebiotic
Helps maintain a healthy gastro-intestinal (GI) function
Q-2009-00231
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
BimunoBT (BGOS) Prebiotic
Supports your natural defences
Q-2009-00230
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data
Gum PeriobalanceTM tablets and chewing gum
Gum PeriobalanceTM, combined with a correct oral hygiene, helps re-balancing the oral microflora and improving oral health
Q-2009-00373

地区9/font>欧盟
标签9/font>疾病风险胶囊健康声称
食品伙伴网提供标准法规解读、舆情监控、合规咨询、申报注册等服务、br/>电询?535-2129301
QQ?891238009
食品标法? border=
实时把握 食品标法动?/span>
请扫码关?span class="color2">食品标法圇/span>

声明9/p>

凡本网所有原?编译文章及图片、图表的版权均属食品伙伴网所有,如要转载,需注明“信息来源:食品伙伴网”、br> 凡本网注明“信息来源:XXX(非食品伙伴网)”的作品,均转载自其他媒体,转载目的在于传递更多的信息,并不代表本网赞同其观点和对其真实性负责、br> 邮箱:law#www.sqrdapp.com(发邮件时请?换成@ QQ?39307733

[ 政策法规搜索] [ 加入收藏] [ 告诉好友] [ 打印本文] [ 关闭窗口]

Baidu
map